Supercharging clinical development with RWE – with Recursion’s Hemanth Kanakamedala

Greater availability of real-world data and real-world evidence is rapidly changing the landscape of drug development.

At Reuters Pharma USA, Hemanth Kanakamedala, vice president of decision science and real-world evidence at Recursion Pharmaceuticals, spoke with editor-in-chief Jonah Comstock about the various ways innovators in the space are working to bring about this sea change, from using multimodal analytics to tackle the problem of choosing and optimising the treatment site to leveraging large language models to write clinical trial protocols.

They discuss the dynamics of bringing these changes to a competitive industry and the way that real-world evidence is having larger effects on the nature of the clinical development process itself and the expectations of regulators.

Tune in below for a deep dive into these powerful waves of change.